Entity

Time filter

Source Type

Amsterdam-Zuidoost, Netherlands

Hasman A.,AMC UvA
Studies in Health Technology and Informatics | Year: 2014

This contribution introduces the Technology Acceptance model. Since information systems are still underutilized, application of models of user acceptance can provide important clues about what can be done to increase system usage. © 2014 The authors and IOS Press. All rights reserved. Source


Jochemsen-van der Leeuw R.,AMC UvA
Huisarts en Wetenschap | Year: 2015

Jochemsen-van der Leeuw HGA, Wieringa-de Waard M, Van Dijk N. The general practitioner as positive role model. Huisarts Wet 2015;58(12):638-40. The general practitioner is a role model for GP trainees during their GP placement, not only with regard to education but also with regard to patient care, practice organization, and personal aspects. Many clinical trainers are not aware that they function as role model, which can lead to them passing on negative behaviour to trainees. In her PhD thesis, the first author investigated the characteristics of a positive role model, and which characteristics facilitate the best transfer of information. After educating GP trainees, information – in the form of knowledge, attitude, and skills – is not always passed from clinical trainer to trainees to patient in an ideal ordered fashion. This is why, during the training of GP trainers, it would be a good idea to pay attention to the positive behaviour of role models and to factors that influence knowledge transfer to trainees. In addition, it is also helpful to provide feedback on role model behaviour. © 2015, Bohn Stafleu van Loghum. Source


Sanders M.E.,International Scientific Association for Probiotics and Prebiotics | Lenoir-Wijnkoop I.,University Utrecht | Salminen S.,University of Turku | Merenstein D.J.,Georgetown University | And 7 more authors.
Annals of the New York Academy of Sciences | Year: 2014

Probiotics and prebiotics are useful interventions for improving human health through direct or indirect effects on the colonizing microbiota. However, translation of these research findings into nutritional recommendations and public health policy endorsements has not been achieved in a manner consistent with the strength of the evidence. More progress has been made with clinical recommendations. Conclusions include that beneficial cultures, including probiotics and live cultures in fermented foods, can contribute towards the health of the general population; prebiotics, in part due to their function as a special type of soluble fiber, can contribute to the health of the general population; and a number of challenges must be addressed in order to fully realize probiotic and prebiotic benefits, including the need for greater awareness of the accumulated evidence on probiotics and prebiotics among policy makers, strategies to cope with regulatory roadblocks to research, and high-quality human trials that address outstanding research questions in the field. © 2014 New York Academy of Sciences. Source


Perry M.,RadboudUMC | Moll Van Charante E.P.,AMC UvA
Nederlands Tijdschrift voor Geneeskunde | Year: 2015

The updated Dementia guideline of the Dutch Geriatrics Society (NVKG) recommends additional testing (e.g. EEG, cerebrospinal fluid, CT/MRI or SPECT scans) only in cases of persisting significant diagnostic uncertainty. This more parsimonious use of tests appears to contrast with the current trend for specialist memory assessment services to favour full test batteries for all patients, and may be more efficient and less burdensome for patients. However, unlike the benchmark Dementia guideline of the Dutch College of General Practitioners (NHG), the NVKG guideline recommends treatment of Alzheimer's disease patients with cholinesterase inhibitors or memantine. Although metaanalyses yield significant beneficial treatment effects, in our opinion these are not clinically relevant and are mostly short-lived and counterbalanced by the burden of adverse effects. Nevertheless, the NVKG guideline also devotes considerable attention to psychosocial interventions that are valuable for the quality of life of both patients and their carers. Source


Chevalier X.,University Paris Est Creteil | Jerosch J.,Klinik fur Orthopadie | Goupille P.,French Institute of Health and Medical Research | Van Dijk N.,AMC UvA | And 4 more authors.
Annals of the Rheumatic Diseases | Year: 2010

Objectives: The primary objective was to compare a single, 6 ml, intra-articular injection of hylan G-F 20 with placebo in patients with symptomatic knee osteoarthritis. The safety of a repeat injection of hylan G-F 20 was also assessed. Methods: Patients with primary osteoarthritis knee pain were randomly assigned to arthrocentesis plus a 6 ml intra-articular injection of either hylan G-F 20 or placebo in a prospective, double-blind (one injector/one blinded observer) study. Results were evaluated at 4, 8, 12, 18 and 26 weeks post-injection. The primary outcome criterion was change from baseline over 26 weeks in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index A pain. Secondary outcome measures included WOMAC A1 and C, patient global assessment (PGA) and clinical observer global assessment (COGA) and Outcome Measures in Rheumatology, Osteoarthritis Research Society International responder rates. A 4-week, open, repeat treatment phase evaluated safety only. Results: A total of 253 patients (Kellgren-Lawrence grade II or III) was randomly assigned. Patients receiving hylan G-F 20 experienced statistically significantly greater improvements in WOMAC A pain scores (20.15, SE 0.076, p = 0.047), and several of the secondary outcome measures (WOMAC A1, PGA and COGA), than patients receiving placebo. There was no difference between the safety results of the two groups. No increased risk of local adverse events was observed in the open, repeat treatment phase. Conclusions: This placebo-controlled study demonstrated that, in patients with knee osteoarthritis, a single 6 ml intra-articular injection of hylan G-F 20 is safe and effective in providing statistically significant, clinically relevant pain relief over 26 weeks, with a modest difference versus placebo. Trial registration number: NCT00131352. Source

Discover hidden collaborations